What does a double‑stranded DNA (dsDNA) enzyme immunoassay result of 1.60 IU/mL (reference range 0–10 IU/mL) indicate?

dsDNA EIA Result of 1.60 IU/mL: Clinical Interpretation

A dsDNA antibody level of 1.60 IU/mL is well within the normal reference range (0–10 IU/mL) and is considered negative, effectively ruling out systemic lupus erythematosus (SLE) in the absence of other compelling clinical or serological findings. 1, 2

Understanding the Result

• This value is far below any clinically significant threshold for anti-dsDNA antibodies and does not meet criteria for SLE classification 1, 2
• The reference range of 0–10 IU/mL represents the normal population baseline, and your result of 1.60 IU/mL falls comfortably within this range 1
• No confirmatory testing with Crithidia luciliae immunofluorescence test (CLIFT) is indicated when the solid-phase assay (SPA) result is this low 1

Clinical Significance

When This Result Rules Out SLE

• In the absence of clinical suspicion for SLE, this negative result effectively excludes the diagnosis 1
• According to 2019 EULAR/ACR classification criteria, anti-dsDNA antibodies are the most prominent immunological criterion for SLE, and a negative result argues strongly against the diagnosis 2
• If antinuclear antibodies (ANA) were tested and are also negative, SLE is essentially ruled out as ANA positivity is now an entry criterion for SLE classification 1, 2

When Additional Evaluation May Be Needed

• If there is high clinical suspicion for SLE despite this negative result (e.g., unexplained multi-system inflammatory disease, cytopenias, nephritis, serositis), further autoantibody testing should be pursued 1
• In rare cases with strong clinical suspicion and positive ANA, consider testing for:
  • Anti-extractable nuclear antigen (anti-ENA) antibodies including anti-Smith, anti-Ro, anti-La 1
  • Anti-nucleosome antibodies (83% sensitivity, 97% specificity for SLE) 1, 2
  • Antiphospholipid antibodies (present in 30–40% of SLE patients) 1, 2

Common Pitfalls to Avoid

• Do not repeat anti-dsDNA testing for disease monitoring when the baseline is negative 1
• Anti-dsDNA antibodies can appear months to years before clinical SLE manifestations, but a value this low (1.60 IU/mL) does not suggest pre-clinical disease 1
• Do not use ANA testing alone to monitor disease activity if SLE is eventually diagnosed; quantitative anti-dsDNA is preferred for monitoring, but only if initially positive 1

What This Result Does NOT Exclude

While this negative anti-dsDNA result argues against SLE, it does not rule out:

• ANA-positive lupus without anti-dsDNA antibodies (approximately 30–40% of SLE patients may be anti-dsDNA negative) 3
• Other connective tissue diseases (mixed connective tissue disease, Sjögren's syndrome, systemic sclerosis) 1
• Drug-induced lupus (which typically has anti-histone antibodies rather than anti-dsDNA) 1

Recommended Next Steps

• If clinical suspicion for SLE is low: No further autoantibody testing is needed 1
• If clinical suspicion persists: Order ANA by immunofluorescence on HEp-2 cells (if not already done) and anti-ENA panel 1
• If unexplained systemic symptoms continue: Consider alternative diagnoses and pursue organ-specific evaluation rather than reflexive repeat autoantibody testing 1